RU2469742C2 - Снижение уровней/активности аргиназы - Google Patents

Снижение уровней/активности аргиназы Download PDF

Info

Publication number
RU2469742C2
RU2469742C2 RU2009106041/15A RU2009106041A RU2469742C2 RU 2469742 C2 RU2469742 C2 RU 2469742C2 RU 2009106041/15 A RU2009106041/15 A RU 2009106041/15A RU 2009106041 A RU2009106041 A RU 2009106041A RU 2469742 C2 RU2469742 C2 RU 2469742C2
Authority
RU
Russia
Prior art keywords
epicatechin
derivative
cocoa
arginase
composition
Prior art date
Application number
RU2009106041/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009106041A (ru
Inventor
Гарольд Х. ШМИТЦ
Кэтрин Л. КВИК-УРИБЕ
Хаген ШРЕТЕР
Original Assignee
Марс, Инкорпорейтед
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Марс, Инкорпорейтед, Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Марс, Инкорпорейтед
Publication of RU2009106041A publication Critical patent/RU2009106041A/ru
Application granted granted Critical
Publication of RU2469742C2 publication Critical patent/RU2469742C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009106041/15A 2006-07-21 2007-07-20 Снижение уровней/активности аргиназы RU2469742C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83268406P 2006-07-21 2006-07-21
US60/832,684 2006-07-21
PCT/US2007/016504 WO2008011173A2 (en) 2006-07-21 2007-07-20 Improvement of arginase levels/activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012137517/15A Division RU2012137517A (ru) 2006-07-21 2012-09-03 Снижение уровней/активности аргиназы

Publications (2)

Publication Number Publication Date
RU2009106041A RU2009106041A (ru) 2010-08-27
RU2469742C2 true RU2469742C2 (ru) 2012-12-20

Family

ID=38957417

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009106041/15A RU2469742C2 (ru) 2006-07-21 2007-07-20 Снижение уровней/активности аргиназы
RU2012137517/15A RU2012137517A (ru) 2006-07-21 2012-09-03 Снижение уровней/активности аргиназы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012137517/15A RU2012137517A (ru) 2006-07-21 2012-09-03 Снижение уровней/активности аргиназы

Country Status (9)

Country Link
US (3) US20080021097A1 (cg-RX-API-DMAC7.html)
EP (2) EP2068941A4 (cg-RX-API-DMAC7.html)
JP (1) JP2010500973A (cg-RX-API-DMAC7.html)
CN (1) CN101516407B (cg-RX-API-DMAC7.html)
AU (1) AU2007275561B2 (cg-RX-API-DMAC7.html)
CA (1) CA2657915A1 (cg-RX-API-DMAC7.html)
IL (1) IL196480A0 (cg-RX-API-DMAC7.html)
RU (2) RU2469742C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008011173A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759025A1 (en) * 2009-04-17 2010-10-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
FR2973234A1 (fr) * 2011-03-31 2012-10-05 Oreal Utilisation cosmetique d'inhibiteur d'arginase, comme agent pour freiner la chute des cheveux, des sourcils et/ou des cils
JP2014521702A (ja) * 2011-08-05 2014-08-28 カーデロ セラピューティクス インコーポレイテッド フラボノイド化合物
US9266260B2 (en) * 2011-12-20 2016-02-23 Massachusetts Institute Of Technology Precision continuous stamp casting method for roll-based soft lithography
WO2014024136A1 (en) * 2012-08-07 2014-02-13 Indus Biotech Private Limited A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication
WO2014120774A1 (en) * 2013-01-29 2014-08-07 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
WO2016046375A1 (en) * 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury
EP3379248B1 (en) * 2015-11-18 2020-09-23 Tokyo Ohka Kogyo Co., Ltd. Arginase activity measurement method, arginase activity detection kit, arginase-related disease detection kit, and arginase inhibitor or active agent screening method
WO2017085947A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット及びアルギナーゼ関連疾患検出キット
JP6925163B2 (ja) * 2017-05-16 2021-08-25 東京応化工業株式会社 尿素の測定方法及び尿素検出キット
CN107815370A (zh) * 2017-11-17 2018-03-20 华坪县腾辉酒业有限公司 一种蓝莓露酒及其制备方法
US11269896B2 (en) 2019-09-10 2022-03-08 Fujitsu Limited System and method for automatic difficulty level estimation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180406A1 (en) * 2002-03-21 2003-09-25 Helmut Sies Treatment of diseases involving defective gap junctional communication
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates
RU2269268C2 (ru) * 1998-03-12 2006-02-10 Марс, Инкорпорейтед Продукты, содержащие полифенол(ы) и l-аргинин, для стимуляции продукции окиси азота

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6469053B1 (en) * 1996-04-02 2002-10-22 Mars Incorporated Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
AU9797998A (en) * 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
US6156912A (en) 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers
JP2001013453A (ja) * 1999-06-28 2001-01-19 Canon Inc 光学装置
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
JP4112764B2 (ja) * 1999-11-19 2008-07-02 株式会社伊勢半 皮膚外用剤
US6627232B1 (en) 2000-06-09 2003-09-30 Mars Incorporated Method for extracting cocoa procyanidins
US20050043408A1 (en) * 2001-10-15 2005-02-24 Faustinus Yeboah Anti-glycation agents for preventing age- diabetes- and smoking-related complications
US20040115285A1 (en) * 2002-12-13 2004-06-17 Peter Rohdewald Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts
US20090047368A1 (en) * 2004-11-04 2009-02-19 University Of Tsukuba Polymeric polyphenol extracted from fermented tea, therapeutic agent for mitochondrial disease, preventive/therapeutic agent for diabetes mellitus, and food or beverage
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
US20060293259A1 (en) * 2005-06-28 2006-12-28 Mars, Incorporated Compositions and methods of use of derivatized flavanols
EP1896442A2 (en) * 2005-06-29 2008-03-12 Mars, Incorporated Thermally-processed cocoa products useful for vascular health improvement
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
RU2269268C2 (ru) * 1998-03-12 2006-02-10 Марс, Инкорпорейтед Продукты, содержащие полифенол(ы) и l-аргинин, для стимуляции продукции окиси азота
US20030180406A1 (en) * 2002-03-21 2003-09-25 Helmut Sies Treatment of diseases involving defective gap junctional communication
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FISHER С. Chocolate - A Help in Treating Diabetes, Strokes & Dementia, 2005. [он-лайн] [Найдено 29.04.2011] найдено в Интернет на http://dietsnutrition.allinfoabout.com/features/chocolate.html. *
FISHER С. Chocolate - A Help in Treating Diabetes, Strokes & Dementia, 2005. [он-лайн] [Найдено 29.04.2011] найдено в Интернет на http://dietsnutrition.allinfoabout.com/features/chocolate.html. SCHROETER H et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans // PNAS, 2006 (Jan 24), V 103, №4, p.1024-1029. ZHU QIN YAN et al. Influence of cocoa flavanols and procyanidins on free radical-induced human erythrocyte hemolysis // Clinical & Developmental Immunology, 2005; 12(1):27-34. *
SCHROETER H et al. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans // PNAS, 2006 (Jan 24), V 103, No.4, p.1024-1029. *
ZHU QIN YAN et al. Influence of cocoa flavanols and procyanidins on free radical-induced human erythrocyte hemolysis // Clinical & Developmental Immunology, 2005; 12(1):27-34. *

Also Published As

Publication number Publication date
IL196480A0 (en) 2009-11-18
WO2008011173A2 (en) 2008-01-24
US20080021097A1 (en) 2008-01-24
WO2008011173A3 (en) 2008-07-03
AU2007275561B2 (en) 2013-12-19
EP2068941A2 (en) 2009-06-17
RU2009106041A (ru) 2010-08-27
RU2012137517A (ru) 2014-03-10
CN101516407B (zh) 2012-03-21
EP2438915A1 (en) 2012-04-11
US20110257119A1 (en) 2011-10-20
EP2068941A4 (en) 2009-09-30
AU2007275561A1 (en) 2008-01-24
CN101516407A (zh) 2009-08-26
US20120015053A1 (en) 2012-01-19
JP2010500973A (ja) 2010-01-14
CA2657915A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
AU2007275561B2 (en) Improvement of arginase levels/activity
JP4970690B2 (ja) 血管の健康状態を改善するための組成物および方法
EP2869717B1 (en) Prevention of alcohol reaction with dietary supplements
US9901564B2 (en) Compounds and compositions for the treatment of muscular disorders
US20190269715A1 (en) Compositions and method of use of a-type procyanidins
US20170136050A1 (en) Anti-glycation methods and compositions
US20160346266A1 (en) Reduction or prevention of alcohol reaction with dietary supplements
KR19980702533A (ko) 프로시아니딘을 유효성분으로 하는 항비만제
MX2008005932A (es) Composiciones para regular trastornos intestinales y metodos de uso de las mismas.
JPWO2012121140A1 (ja) 成長ホルモン分泌促進剤
JP2009501161A (ja) 血管系の健康改善に有用な熱処理されたカカオ製品
RU2587321C2 (ru) Возбуждение вазодилатации периферических кровеносных сосудов
US20220387464A1 (en) Inositol phosphate-containing composition
US20070004652A1 (en) Treatment of occlusive thrombosis
KR20220118504A (ko) 비만 억제용 조성물
JP2008502691A (ja) 二量体ジガレートの組成物および使用方法
WO2014143192A1 (en) Reduction or prevention of alcohol reaction with dietary supplements
CN119013011A (zh) 用于代谢健康的ampk活化剂(cbda)和sglt2抑制剂
WO2007084648A2 (en) Mixed 4→6 procyanidin dimers and their use
HK1210388B (en) Prevention of alcohol reaction with dietary supplements
KR20100137674A (ko) 리나룰을 유효성분으로 함유하는 콜레스테롤 저하용 조성물